Du är här


Swedish Orphan Biovitrum AB (publ): Sobi publishes Report for the First Quarter 2014

SwedishOrphan Biovitrum AB (publ) (Sobi) today announced its results for the
quarter 2014. R
evenues totalled SEK 573.3 M (528.5), an increase of 8 per cent. The Partner
Products portfolio was a highlight, with 70 per cent growth compared to the
first quarter last year.

Business Highlights Q1 2014

* US FDA approved Alprolix(TM)
* Kiobrina® pivotal phase 3 study did not meet primary endpoint
* Cometriq(TM) approved in Europe for the treatment of Medullary Thyroid
* Health Canada approved Alprolix
* Sobi received EURORDIS Company Award 2014

Financial Highlights Q1 2014 (Q1 2013)

* Total revenues were SEK 573.3 M (528.5)
* Gross margin was 56 per cent (57)
* EBITA was SEK -287.8 M (61.2)
* EBITA excluding Kiobrina write-off was SEK 37.1 M
* Ended the quarter with a cash position of SEK 573.7 M

"Sobi delivered a solid start to the year, with revenues growing 8 per cent
year-on-year to reach the second highest quarterly level in the company's
history. Our Partner Products portfolio was a highlight with 70 per cent
growth compared to the first quarter last year. Our pipeline also reached
several important milestones albeit with mixed results in the period. Our
pivotal phase 3 study of the enzyme therapy Kiobrina did not meet its primary
endpoint, and our report reflects the full financial impact of this outcome
for the company", said Geoffrey McDonough, CEO and President. "Shortly after
the quarter closed, we released positive top-line results of the Kids A-LONG
phase 3 clinical study for Eloctate(TM) together with our partner Biogen
Idec. This important step brings this potential new treatment option closer
to adults and children with haemophilia A, and it enables a regulatory
submission in Europe later this year. We were also pleased to initiate direct
sales for Orfadin in North America on 1 April, and expect Orfadin to return
to normal revenues with higher margins as a result."

|Financial Summary |
|Amounts in SEK M Q1 2014 Q1 2013 Full Year 2013 |
|Total revenues 573.3 528.5 2 176.7 |
|Gross profit 319.7 302.9 1 284.0 |
|Gross margin 56% 57% 59% |
|EBITA -287.8 61.2 211.0 |
|EBITA excluding Kiobrina write-off 37.1 61.2 211.0 |
|EBIT (Operating profit/loss) -358.0 -3.4 -66.6 |
|Profit/loss for the period -328.7 -12.2 -93.0 |

Sobi's report for the first quarter 2014 can be found

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of
specialty and rare disease products for partner companies. Sobi is a pioneer
in biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
($334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available atwww.sobi.com.

|For more information please contact |
|Media relations Investor relations |
|Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
|T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
|oskar.bosson@sobi.com jorgen.winroth@sobi.com |
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on 8 May 2014.

Sobi Report for the First Quarter 2014


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.